Oasis reports failures including wrong compounds, low purity and off-label doses in BPC-157, semaglutide and Melanotan II, and says Peptide Gurus passed 9 of 46.
Recap by typeshit. Post by Oasis on X.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Speaking at #CCC2026, the researcher walks through what GLP-1 drugs for diabetes and weight loss do. Shared by the Canadian Cardiovascular Society.
Oasis Health says Peptides For Sale passed none of 23 tests, with vials of BPC-157 and semaglutide that weren't what the label said or fell short on purity.
Loading…